Journal of Clinical Oncology
Articles in this Issue
Camrelizumab plus albumin-bound paclitaxel and S-1 as first-line treatment of HER-2 negative unresectable locally advanced or advanced gastric and gastroesophageal junction adenocarcinoma: A phase II clinical trial.
4038 Background: Gastric cancer is a common malignant tumor of the digestive tract. For nearly 90% of HER2 negative advanced gastric and gastroesophageal...
A first-in-human trial of intravesical BH011, a novel docetaxel formulation, in patients with high risk non-muscle invasive bladder cancer (HR-NMIBC) after BCG failure: Results from a phase 1 study.
e16605 Background: BH011 is a novel docetaxel formulation for intravesical administration that significantly increased the concentration of free docetaxel...
The impact of obesity on survival in non-small cell lung cancer patients receiving immune checkpoint inhibitor therapy: A retrospective multi-institutional US cohort study.
e20630 Background: Immune checkpoint inhibitor (ICI) therapy is a cornerstone in the treatment of metastatic non-small cell lung cancer (NSCLC). However,...
Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial.
4590 Background: UTUC is rare and highly aggressive. The prognosis is poor, especially for high-risk patients, even after radical surgery. Adjuvant chemot...
Clinical characteristics and survival outcomes in uterine carcinosarcoma: A population-based analysis.
e17647 Background: Uterine carcinosarcoma (UCS), a rare and aggressive malignancy, representing less than 5% of uterine cancers but accounts for 16% of ut...
Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy.
1010 Background: ctDNA monitoring during adjuvant endocrine therapy is an opportunity to detect molecular relapse before clinically apparent recurrence. c...
Clinical outcomes with statins and CDK4/6 inhibitors in patients with metastatic HR+/HER2- breast cancer.
e13093 Background: With the increasing use of cyclin-dependent kinase inhibitors (CDK4/6i) combined with endocrine therapy (ET) as the standard first-line...
Real world analysis comparing chemoradiation with durvalumab vs chemoradiation alone in locally advanced, unresectable, stage III non-small cell lung cancer.
e20084 Background: In the randomized phase III PACIFIC trial, combining durvalumab with chemoradiation (CRT) resulted in an improvement in overall-surviva...
Efficacy of pharmacological interventions in alveolar soft part sarcoma: A network meta-analysis.
e23563 Background: Alveolar soft part sarcoma (ASPS) is a very rare sarcoma of uncertain histogenesis, first described in 1952 by Christopherson, then a f...
Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
6060 Background: The poor prognosis of locoregionally advanced nasopharyngeal carcinoma (LANPC) due to the high incidence of metastasis necessitates effec...
Seasonal impact of anti–PD-1 treatment initiation in non-small cell lung cancer patients.
e20617 Background: Daily and annual variation of immune parameters has been described (Wyse et al., 2021). We and others have correlated the time-of-day o...
In silico evaluation of the interaction of P-gp and 3A4 substrates with the WEE1 inhibitor Debio 0123 and clinical application in the Debio 0123-104 combination trial with carboplatin and etoposide.
e15127 Background: Debio 0123 is an oral, brain-penetrant, highly selective WEE1 kinase inhibitor currently being investigated in several clinical trials...
ctDNA dynamics and targeted therapies associated with genetic mutations in patients with colorectal cancer.
3597 Background: Colorectal cancer (CRC) is a heterogeneous disease with various genetic mutations that guide targeted therapy decisions, as outlined by N...
Trends and disparities in mortality due to myelodysplastic syndromes in the US from 1999 to 2020.
e18586 Background: Myelodysplastic syndrome (MDS) is a group of hematological disorders characterized by ineffective hematopoiesis and an increased risk o...
A multicenter, randomized controlled trial of intrapleural drug-loaded vesicle perfusion combined with systemic therapy for malignant pleural effusion.
3152 Background: This study aimed to evaluate the efficacy and safety of drug-loaded vesicle (DLV) intrapleural perfusion combined with systemic therapy i...
Association of <i>IL7</i> germline variants with immune-related adverse events (irAEs) in cancer patients (pts) treated with immune checkpoint inhibitors (ICIs).
12129 Background: Despite the transformative impact of ICIs on cancer treatment, their efficacy remains limited by adverse events (AEs), underscoring the...
JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies.
1028 Background: JSKN003 is a biparatopic HER2-targeting antibody-drug conjugate (ADC) conjugated to a topoisomerase I inhibitor (TOP1i) via a tetrapeptid...
Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study.
e13007 Background: In previous clinical trials, pyrotinib has shown good antitumor activity and manageable toxicity in human epidermal growth factor recep...
Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study.
11501 Background: Anthracycline-based chemotherapy has been the standard first-line treatment for advanced STS for decades. The phase 3 ANNOUNCE trial fai...
Prognostic biomarkers for colorectal cancer in a Nigerian population.
e15575 Background: Colorectal cancer (CRC) is a significant global health disease, with over one million new cases and more than 500,000 deaths in 2018. T...
Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.
TPS3172 Background: SG is a Trop-2 directed antibody drug conjugate that has shown an overall survival benefit for patients (pts) with HER2- ABC in two ph...
Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.
6004 Background: The addition of PD-1 inhibitor to gemcitabine and cisplatin (GP) showed promising activity as first-line therapy for R/M NPC. Here, we fi...
Induction chemotherapy using gemcitabine and cisplatin followed by hypofractionated radiotherapy in advanced head and neck squamous cell carcinoma.
e18010 Background: The mainstay of treatment for locally advanced head and neck squamous cell carcinoma (HNSCC) is definitive concurrent chemoradiation (C...
Feasibility and clinical outcomes of imatinib personalized dosing in gastrointestinal stromal tumor patients.
11521 Background: Imatinib treatment for metastatic gastrointestinal stromal tumors (GISTs) has substantial overall survival benefits compared to chemothe...
Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study.
3569 Background: Immune checkpoint inhibitors (ICIs) are a standard treatment for gastrointestinal (GI) cancers with mismatch repair deficiency (dMMR) or...